Ascendis Pharma A/S (ASND)
NASDAQ: ASNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ASND stock chart
Technical analysisKey statistics
All statistics- Market cap
- $15.03B
- P/E (TTM)
- 17.50
- Forward P/E
- 21.11
- EPS (TTM)
- $13.05
- Dividend yield
- None
- 52-week range
- 186.05 – 282.15
- Day range
- 223.05 – 229.00
- Volume / Avg
- 820.54K / 658.78K
- Beta
- —
- Shares outstanding
- 65.80M
52-week range
ASND stock today
Shares of Ascendis Pharma A/S (ASND) finished higher on Oct 7 at $228.41, a gain of 1.04% or $2.36 per share, versus the S&P 500's 0.22% decline. At this level, ASND sits in the middle of its 52-week range of $186.05 to $282.15: 19.0% below the high, set on Jul 9, 2026 and 22.8% above the low. ASND is up 7.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 8.8%.
At 17.5x trailing earnings, Ascendis Pharma A/S trades below the peer-group median of 88.5x. Its forward P/E of 21.1x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Ascendis Pharma A/S
Company profileAscendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Jan Moller Mikkelsen
- Headquarters
- Hellerup
- Employees
- 1,189
- IPO year
- 2015
- Website
- ascendispharma.com
Analyst forecast
ForecastConsensus (20 analysts)
strong_buy
Avg. price target
$305.84+33.90%
- Strong buy 5
- Buy 15
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
ASND news
All ASND news- Wednesday's ETF with Unusual Volume: PIEQNasdaqPIEQ, VALE, TSM, ASND
- Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG DealsNasdaqAPVO, ASND, AZN, BIIB
- Pre-Market Earnings Report for August 13, 2026 : BN, JD, TPR, ASND, AIT, MSGS, BIRK, GDS, ONDS, CLBT, YETI, BLSHNasdaqBN, JD, TPR, ASND
Ascendis Pharma A/S peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| JAZZJazz Pharmaceuticals plc | 231.19 | -0.09% | $15.01B | vs ASND |
| SMMTSummit Therapeutics Inc. | 17.95 | +3.70% | $14.32B | vs ASND |
| BBIOBridgeBio Pharma Inc. | 66.50 | -0.69% | $13.00B | vs ASND |
| CORTCorcept Therapeutics Incorporated | 119.60 | +0.03% | $12.93B | vs ASND |
| MDGLMadrigal Pharmaceuticals Inc. | 487.72 | -1.76% | $11.27B | vs ASND |
| ELANElanco Animal Health Incorporated | 22.36 | -0.53% | $11.17B | vs ASND |
| BMRNBioMarin Pharmaceutical Inc. | 55.20 | -1.81% | $10.69B | vs ASND |
| RDYDr. Reddy's Laboratories Ltd | 12.27 | -1.76% | $10.22B | vs ASND |
Indexes, lists and sector
Ascendis Pharma A/S stock FAQ
What is Ascendis Pharma A/S's stock price today?
ASND last traded at $228.41 as of Oct 7, 4:00 PM EDT, up 1.04% on the day. Prices are delayed at least 15 minutes.
What is ASND's P/E ratio?
ASND trades at a trailing P/E ratio of 17.50 and a forward P/E of 21.11, compared with a median of 88.5 for its closest peers.
Who is Ascendis Pharma A/S's CEO?
Mr. Jan Moller Mikkelsen is the chief executive officer of Ascendis Pharma A/S, which has about 1,189 employees.
What is the ASND 52-week high?
The 52-week high for ASND is $282.15 and the 52-week low is $186.05. The stock is currently 19.0% below its high.